This inventor holds 1 USPTO granted patent. Top assignee: Peking University. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Innovations in Ovarian Cancer Treatment by Xiaohong Chang
Introduction
Xiaohong Chang is a notable inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the development of innovative treatments for ovarian cancer. His work focuses on the use of T-cell epitope peptides to enhance the efficacy of anti-idiotypic antibodies.
Latest Patents
Xiaohong Chang holds a patent for "T cell epitope peptides of ovarian cancer anti-idiotypic antibody 6B11 and use thereof." This invention provides two T-cell epitope peptides derived from the anti-idiotype antibody 6B11, specifically designed to target ovarian cancer cells. The sequences of these peptides are detailed in SEQ ID NO:3 or 6. The patent outlines the potential use of these peptides in the manufacture of vaccines aimed at treating and preventing ovarian cancer. The T-cell epitope peptides have shown the ability to specifically kill OC166-9 positive ovarian cancer cells, indicating their promising application in cancer therapy.
Career Highlights
Xiaohong Chang is affiliated with Peking University, where he conducts research and develops innovative solutions for cancer treatment. His work has garnered attention for its potential to improve patient outcomes in ovarian cancer therapy.
Collaborations
Xiaohong Chang collaborates with esteemed colleagues, including Huifang Guo and Wei Li, who contribute to his research efforts in the field of cancer immunotherapy.
Conclusion
Xiaohong Chang's innovative work in developing T-cell epitope peptides represents a significant advancement in the fight against ovarian cancer. His contributions have the potential to lead to more effective treatments and improved patient care.